Trial Profile
A Phase I Study of Carboplatin and nab-Paclitaxel plus concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Mar 2020
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 31 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 04 Mar 2014 New trial record